In a recent legal development, pharmaceutical company Sandoz Inc. has been awarded $70.5 million in damages following a decision by a federal judge. U.S. District Judge Brian Martinotti ruled that Sandoz suffered lost profits due to United Therapeutics’ actions regarding the generic sales of treprostinil, a medication used to treat pulmonary arterial hypertension. The judge stated that these lost profits were a “natural and probable consequence” of United Therapeutics’ breach of promise.
In his decision, Judge Martinotti pointed to the blockage of Sandoz’s product launch, which impacted the company’s financial trajectory. The legal battle highlights ongoing tensions in the pharmaceutical industry, where brand-name drug producers often face off against generic drug manufacturers over market access and competition.
For further insights and details on this case, please visit the original report.